Clopidogrel transfer into human milk: case series – a contribution from the ConcePTION project
The estimated infant exposure to CLP and its metabolites via human milk was low in both cases. Although this low exposure was supported by the observed infant plasma concentration, additional studies should confirm CLP safety via human milk, especially considering known variable pharmacokinetics and ontogeny of metabolizing enzymes in infants.
Authors
- Kaytlin Krutsch (ORCID: https://orcid.org/0000-0002-7453-2582)
- Michael Ceulemans (ORCID: https://orcid.org/0000-0002-4130-5869)
- Anneke Passier (ORCID: https://orcid.org/0000-0001-5594-6360)
- Nina Nauwelaerts (ORCID: https://orcid.org/0000-0001-5301-6813)
- Pieter Annaert (ORCID: https://orcid.org/0000-0003-3525-7351)
- Raf Mols
- Anne Smits (ORCID: https://orcid.org/0000-0002-0710-6698)
- Karel Allegaert (ORCID: https://orcid.org/0000-0001-9921-5105)
- Martje Van Neste (ORCID: https://orcid.org/0000-0002-0424-450X)
Institutions
- Texas Tech University (US)
- Erasmus MC (NL)
- Research Foundation - Flanders (BE)
- Netherlands Pharmacovigilance Centre Lareb (NL)
- Texas Tech University Health Sciences Center (US)
- KU Leuven (BE)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.3389/fphar.2025.1499243
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- European Federation of Pharmaceutical Industries and Associations
- Fonds Wetenschappelijk Onderzoek
- KU Leuven
- HORIZON EUROPE Framework Programme